Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Spotlight

GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines

Business

Deals
Earnings
Manufacturing

Policy & Regulation

Regulatory Landscape
Drug Pricing
IP & Litigation

Tools & Trackers

What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings

Conference Coverage

Partner Insights

Generics Bulletin Perspectives

Exploring market-shifting topics for the off-patent sector.

Generics Bulletin

Medtech Insight

Hyloris On Track To Meet 2024 Target During Half-Year Update

Company Aims To Expand Its Portfolio To 30 Products By 2024

Sep 05 2022

• By Chloe Kent

Train approaching train station on top of Mount Rigi in canton of Schwyz, Switzerland — Hyloris remains on track to meet its 2024 ambitions, according to the company's CEO • Source: Shutterstock

Related Content

Hyloris Buys Out Maxigesic IV Royalty Rights From Alter Pharma

Jun 28 2021

Hyloris And Purna Strike Value-Added Development Deal

Sep 19 2025

Hyloris Teams Up With Vaneltix For Value-Added Interstitial Cystitis Pain Treatment

Dec 20 2021

FDA Asks Hyloris For More Data On Maxigesic IV

Jul 05 2022

Hyloris Raises €15m In Private Equity Offering

Apr 19 2022

Related Companies

Hyloris Pharmaceuticals SA

Vaneltix Pharma, Inc.

Alter Pharma Group

Additional Topics

Sales & Earnings Strategy Value-Added Medicines BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window